A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants with Stage III Unresectable NSCLC - PACIFIC-8

Exclusion Criteria

• 1. History of another primary malignancy, except for:
• -Malignancies treated with curative intent and adequate follow-up with no known active disease and have not required active treatment within the past 3 years before the first dose of study intervention and of low potential risk of recurrence.
• -Adequately resected non melanoma skin cancer or lentigo maligna without evidence of disease .
• -Adequately treated carcinoma in situ, including Ta tumors without evidence of disease.
• 2. Mixed small cell and non-small cell lung cancer histology.
• 3. Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
• 4. Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
• 5. Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
• 6. Participants with ≥ grade 2 pneumonitis from prior chemoradiation therapy.
• 7. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis – regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis
• 8. Active or prior documented autoimmune or inflammatory disorders (with exceptions)
• 9. Active EBV infection, or known or suspected chronic active EBV infection at screening
• 10. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.